Form 4: Alnylam Executive Reports Routine Stock Transactions

Alnylam Pharmaceuticals' CSO and EVP, Kevin Fitzgerald, reported a series of stock acquisitions and sales, including RSU grants, option grants, and sales for tax obligations and a 10b5-1 plan.

Summary

• Kevin Joseph Fitzgerald, CSO & EVP, Head of Research at Alnylam Pharmaceuticals, Inc. (ALNY), reported multiple transactions involving the company's common stock and derivative securities.
• On March 2, 2026, Fitzgerald acquired 3,688 shares of Common Stock through Restricted Stock Units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan, vesting over three years.
• Also on March 2, 2026, Fitzgerald acquired 8,105 Stock Options with an exercise price of $325.07, vesting over a four-year period.
• On March 2, 2026, a total of 1,508 shares of Common Stock were automatically sold by the company on Fitzgerald's behalf to cover minimum statutory tax withholding obligations related to awards, at weighted average prices ranging from $323.62 to $332.64.
• On March 3, 2026, a total of 1,652 shares of Common Stock were sold pursuant to a Rule 10b5-1(c) trading plan adopted on August 14, 2025, at weighted average prices ranging from $316.55 to $321.58.
• Fitzgerald also indirectly acquired 537 shares of ALNY common stock through a managed account as a result of the issuer's 401(k) matching contribution program.
• Following these reported transactions, Fitzgerald directly beneficially owns 21,860 shares of Common Stock and 8,105 Stock Options, and indirectly owns 537 shares of Common Stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing. While there are insider sales, they are largely routine for tax purposes and pre-scheduled, offset by new equity grants that align executive interests with long-term company performance.

Positives

• Grant of 3,688 Restricted Stock Units (RSUs) on March 2, 2026, aligning executive interests with long-term shareholder value through a three-year vesting schedule.
• Grant of 8,105 stock options on March 2, 2026, with an exercise price of $325.07, providing future upside potential and further aligning executive incentives.
• Acquisition of 537 shares of ALNY common stock through the company's 401(k) matching contribution program, demonstrating ongoing employee benefits and investment in the company.

Negatives

• Sales of 1,508 shares of common stock on March 2, 2026, to cover tax withholding obligations, reducing direct beneficial ownership.
• Sales of 1,652 shares of common stock on March 3, 2026, under a pre-arranged 10b5-1 trading plan, further reducing direct beneficial ownership.

Future Outlook

The Restricted Stock Units (RSUs) granted on March 2, 2026, will vest over a three-year period, with one-third vesting on each of the first, second, and third anniversaries of the grant date. The stock options granted on March 2, 2026, will vest as to 25% of the shares on the first anniversary of the grant date and the remaining shares will vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date.

Industry Context

StockSavvy.ai notes that routine insider transactions, especially those for tax purposes or pre-scheduled 10b5-1 plans, are common in the biotechnology and pharmaceutical sectors as part of executive compensation and wealth management strategies. These transactions typically do not reflect a change in the company's fundamental outlook or broader industry trends.

Stakeholder Impact

• Shareholders: Routine insider transactions, including grants and pre-planned sales, are generally expected and do not typically signal a major shift in company prospects. The grants align executive incentives with shareholder value.
• Employees: The 401(k) matching contribution program benefits employees who participate.

Next Steps

• Vesting of RSUs on the first, second, and third anniversaries of March 2, 2026.
• Vesting of stock options over a four-year period, starting with 25% on March 2, 2027, and quarterly thereafter until March 2, 2030.

Key Dates

Recommendation

The filing details routine insider transactions, including equity grants and pre-scheduled sales for tax purposes and a 10b5-1 plan. These actions are typical for executives and do not provide new fundamental information to warrant a change in investment thesis. The grants align executive interests, while the sales are largely administrative. Therefore, a 'hold' recommendation is appropriate as there's no new information to suggest a significant change in the company's outlook.

Keywords

ALNYLAM, ALNY, insider trading, Form 4, stock options, RSU, 10b5-1, executive compensation, Kevin Fitzgerald